Zhujing Hao

Dr. Zhujing Hao


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
ZHZhujing Hao
Zhujing Hao
GXGuiwen Xu
Guiwen Xu
MYMengyang Yuan
Mengyang Yuan
RTRuopeng Tan
Ruopeng Tan
YXYunlong Xia
Yunlong Xia
XYXiaomeng Yin
Xiaomeng Yin
Vascular aging is associated with metabolic remodeling, and most studies focused on fatty acid and glucose metabolism. Based on our metabolomic data, leucine was significantly reduced in the aortas of aged mice. Whether leucine supplementation can reverse aging-induced vascular remodeling remains unknown. To investigate the effectiveness of leucine, male mice at 15 or 18 months were supplemented with leucine (1.5%) for 3 months. All the aged mice, with or without leucine, were sacrificed at 21 months. Blood pressure and vascular relaxation were measured. H&E, Masson’s trichrome, and Elastica van Gieson staining were used to assess aortic morphology. Vascular inflammation, reactive oxidative stress (ROS), and vascular smooth muscle cell (VSMC) phenotype were also measured in mouse aortas. Compared with the 21-month-old mice without leucine, leucine supplementation from 15 months significantly improved vascular relaxation, maintained the contractile phenotype of VSMCs, and repressed vascular inflammation and ROS levels. These benefits were not observed in the mice supplemented with leucine starting from 18 months, which was likely due to the reduction in leucine transporters Slc3a2 or Slc7a5 at 18 months. Furthermore, we found benefits from leucine via activating the Sirt1-induced Foxo1 deacetylation. Our findings indicated that leucine supplementation in middle-aged mice improved aging-induced vascular remodeling and dysfunction.

28 October 2026 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
BGBoyu Guan
Boyu Guan
XLXinsheng Li
Xinsheng Li
JZJiahua Zhang
Jiahua Zhang
DYDongyuan Yu
Dongyuan Yu
YPYujian Peng
Yujian Peng
ZHZhujing Hao
Zhujing Hao
Background: ST-segment elevation myocardial infarction (STEMI) with cardiogenic shock carries high mortality, yet optimal treatment remains uncertain in this distinct patient population. The aim of this study is to systematically evaluate and compare the efficacy of mechanical circulatory support (MCS) devices, vasoactive agents, and inotropic agents in the management of critical adult patients with STEMI complicating cardiogenic shock. Methods: A network meta-analysis (PROSPERO CRD420251002524) was conducted, with systematic searches of six databases (Embase, Web of Science, PubMed, and Cochrane, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform) from inception to March 2025 for randomized and observational studies. We also updated the search to September 2026 using the same search strategy. Results: Data from 22 studies (pooled n = 360,235) revealed a predominantly male (65%), older adult population (mean age 67 years), US-based (97.9%) population with hypertension, hyperlipidemia, diabetes or heart failure. Compared with intra-aortic balloon pump (IABP), based on observational evidence, Impella was associated with a significantly higher risk of short-term mortality (odds ratio [OR] 1.68, 95% confidence interval [CI] 1.49–1.89), bleeding (OR 1.62, 95% CI 1.49–1.75), stroke (OR 2.67, 95% CI 1.01–7.03), AKI (OR 1.55, 95% CI 1.10–2.18), and AKI requiring dialysis (OR 1.67, 95% CI 1.50–1.87). Compared with control, Impella significantly increased the risk of stroke (OR 4.37, 95% CI 3.74–5.11). Randomized controlled trials (RCTs) have also supported an increased bleeding risk with Impella compared with IABP or standard care. Conclusion: For STEMI patients with cardiogenic shock, IABP may be considered as a mechanical support option when hemodynamically feasible. By contrast, Impella has been associated with an unfavorable risk-benefit profile in this population in observational studies, which may be heavily influenced by patient selection and salvage use. Therefore, its application warrants careful consideration if escalation is necessary. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251002524 , PROSPERO CRD420251002524.